Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension trial of oral nintedanib in systemic sclerosis-associated interstitial lung disease
2016-003403-66Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Boehringer Ingelheim. Started Sep 2017; status: completed.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2016-003403-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003403-66.